miR-21, An Oncogenic Target miRNA for Cancer Therapy: Molecular Mechanisms and Recent Advancements in Chemo and Radio-resistance

Javanmardi, Sanaz; Aghamaali, Mahmoud Reza; Abolmaali, Samira Sadat; Mohammadi, Samaneh; Tamaddon, Ali Mohammad

doi:10.2174/1566523217666170102105119

Cited by 58 publications

(34 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although AACTTT/AAAGTT is not labeled as a binding motif for a known transcription factor (TF), IRF1 is listed as the binding TF for this motif in (Xie et al, 2005). Among other binding partners, mir21 (Feng and Tsao, 2016; Javanmardi et al, 2017), mir204 (Li et al, 2016), mir211 Mazar et al, (2016), FOXO4 (Liu et al, 2011; Hornsveld et al, 2018), LEF1 (Hovanes et al, 2001; Li et al, 2009), ETS2 (Sizemore et al, 2017; Fry and Inoue, 2018) are all discussed in the context of a cancer.…”

Section: Resultsmentioning

confidence: 99%

A Higher Proportion of Craniosynostosis Genes Are Cancer Driver Genes

Misra

Shih

Yan

et al. 2019

Preprint

View full text Add to dashboard Cite

Craniosynostosis (CRS) is a congenital abnormality deformity with a heterogenous genetic contribution. Previously, there are two attempts to collect genes that are genetically associated with craniosynostosis and some related syndromes with 57 (Twigg and Wilkie, 2015) and 39 (Goos and Mathijssen, 2019) genes identified, respectively. We expanded this list of craniosynostosis genes by adding another 17 genes with an updated literature search. These genes are shown to be more likely to be intolerant to functional mutations. Of these 113 craniosynostosis genes, 21 (19% vs. 1.5% baseline frequency) are cancer driver genes, a 14-fold enrichment. The cancer-craniosynostosis connection is further validated by an over-representation analysis of craniosynostosis genes in KEGG cancer pathway and several cancer related gene-sets. Many cancer-craniosynostosis overlapping genes participate in intracellular signaling pathways, which play a role in both development and cancer. This connection can be viewed from the oncogenesis recapitulates ontogenesis framework. Nineteen craniosynostosis genes are transcription factor genes (16.8% vs. 8.2% baseline), and craniosynostosis genes are also enriched in targets of certain transcription factors or micro RNAs.

show abstract

Section: Resultsmentioning

confidence: 99%

A Higher Proportion of Craniosynostosis Genes Are Cancer Driver Genes

Misra

Shih

Yan

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…miR-210 is considered to be a general hypoxamiR, as its expression is observed in a wide array of tumors displaying a hypoxic environment [52]. On the other hand, miR-21 is overexpressed in many different tumors, and could be regarded as a wide-spread oncogenic molecule [53]. Unfortunately, there are no mechanistic studies yet showing the relevance of miR-210 and miR-21 in ACC tumorigenesis.…”

Section: Mirnas As Potential Biomarkersmentioning

confidence: 99%

Non-Coding RNAs in Adrenocortical Cancer: From Pathogenesis to Diagnosis

Decmann

Perge

Turai

et al. 2020

Cancers

View full text Add to dashboard Cite

Non-coding RNA molecules including microRNAs and long non-coding RNAs (lncRNA) have been implicated in the pathogenesis of several tumors and numerous data support their applicability in diagnosis as well. Despite recent advances, the pathogenesis of adrenocortical cancer still remains elusive and there are no reliable blood-borne markers of adrenocortical malignancy, either. Several findings show the potential applicability of microRNAs as biomarkers of malignancy and prognosis, and there are some data on lncRNA as well. In this review, we present a synopsis on the potential relevance of non-coding RNA molecules in adrenocortical pathogenesis and their applicability in diagnosis from tissue and blood.

show abstract

“…MiR-21 was the first miRNA discovered that was upregulated in GBM [ 239 ] and is the most widely studied tumor-promoting miRNA in various cancers. We and others have provided detailed reviews of its expression and cancer-associated functions previously [ 240 , 241 ]. MiR-21 is encoded in a plastic, frequently activated chromosome 17q23 locus, and its high expression is a characteristic feature of multiple malignancies.…”

Section: Microrna Normalization By Otmentioning

confidence: 99%

Oligonucleotide Therapeutics as a New Class of Drugs for Malignant Brain Tumors: Targeting mRNAs, Regulatory RNAs, Mutations, Combinations, and Beyond

Krichevsky

Uhlmann

2019

Neurotherapeutics

View full text Add to dashboard Cite

Malignant brain tumors are rapidly progressive and often fatal owing to resistance to therapies and based on their complex biology, heterogeneity, and isolation from systemic circulation. Glioblastoma is the most common and most aggressive primary brain tumor, has high mortality, and affects both children and adults. Despite significant advances in understanding the pathology, multiple clinical trials employing various treatment strategies have failed. With much expanded knowledge of the GBM genome, epigenome, and transcriptome, the field of neuro-oncology is getting closer to achieve breakthrough-targeted molecular therapies. Current developments of oligonucleotide chemistries for CNS applications make this new class of drugs very attractive for targeting molecular pathways dysregulated in brain tumors and are anticipated to vastly expand the spectrum of currently targetable molecules. In this chapter, we will overview the molecular landscape of malignant gliomas and explore the most prominent molecular targets (mRNAs, miRNAs, lncRNAs, and genomic mutations) that provide opportunities for the development of oligonucleotide therapeutics for this class of neurologic diseases. Because malignant brain tumors focally disrupt the blood–brain barrier, this class of diseases might be also more susceptible to systemic treatments with oligonucleotides than other neurologic disorders and, thus, present an entry point for the oligonucleotide therapeutics to the CNS. Nevertheless, delivery of oligonucleotides remains a crucial part of the treatment strategy. Finally, synthetic gRNAs guiding CRISPR–Cas9 editing technologies have a tremendous potential to further expand the applications of oligonucleotide therapeutics and take them beyond RNA targeting.

show abstract

miR-21, An Oncogenic Target miRNA for Cancer Therapy: Molecular Mechanisms and Recent Advancements in Chemo and Radio-resistance

Cited by 58 publications

References 0 publications

A Higher Proportion of Craniosynostosis Genes Are Cancer Driver Genes

A Higher Proportion of Craniosynostosis Genes Are Cancer Driver Genes

Non-Coding RNAs in Adrenocortical Cancer: From Pathogenesis to Diagnosis

Oligonucleotide Therapeutics as a New Class of Drugs for Malignant Brain Tumors: Targeting mRNAs, Regulatory RNAs, Mutations, Combinations, and Beyond

Contact Info

Product

Resources

About